The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published on September 1
The shift from hospital visits to at-home treatments is accelerating, creating massive opportunities for companies that make this transition possible.
Advanced autoinjectors and smart delivery systems are transforming how patients receive life-changing treatments, opening up entirely new markets.
As patients gain more control over their treatment, companies enabling this independence are positioned for significant growth in the expanding healthcare market.
The FDA's approval of an at-home injectable Alzheimer's drug represents a pivotal shift towards self-administered chronic disease treatments. This creates a compelling investment opportunity in the ecosystem of companies enabling decentralised healthcare, from advanced drug delivery systems to patient monitoring technologies.
This group focuses on growth-oriented companies that specialise in making long-term therapies more accessible and less burdensome for patients. The theme captures the transition from hospital-based treatments to at-home care, which could dramatically improve patient adherence and quality of life.
These companies were handpicked by professional analysts for their integral role in the at-home treatment value chain. They include specialists in autoinjectors, pre-filled syringes, patient monitoring technologies, and specialised logistics for temperature-sensitive biologics.
Market capitalisation breakdown for the At-Home Treatment Revolution basket focused on FDA approval impact.
TNDM: $1.04B
PODD: $23.16B
EMBC: $836.34M
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+4
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
In 12 months it might be worth:
+188.95%
On average, analysts expect assets in this group to grow 188.95% over the next year.
11 of 13 assets in this group are rated Buy by professional analysts.
